You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View
See if you qualify for our free healthcare professional magazines. Click here to start your application for Pre-Diabetes Health, Diabetes Health Pharmacist and Diabetes Health Professional.
Latest Food Articles
Popular Food Articles
Highly Recommended Food Articles
Yale researchers believe that blocking a brain enzyme that affects appetite and energy levels could provide a new treatment for obesity and type 2 diabetes.
Researchers at Yale School of Medicine in New Haven, Connecticut, have found a brain enzyme that, when blocked, curbs appetite and increases energy levels-both crucial factors in controlling and losing weight.
Their results could lead to the development of a drug to counter obesity and type 2 diabetes. In type 2, weight loss and a high energy level, which helps the body metabolize blood sugar, have been a classic combination for controlling the disease.
The enzyme, called prolylcarboxypeptidase (PRCP), regulates chemical alpha-melanocyte stimulating hormone (alpha-MSH), which reduces appetite and increases the body's energy levels. If PRCP "over-regulates" alpha-MSH, however, the body experiences greater appetite and a lessening of energy output.
The Yale scientists blocked PRCP from working in nondiabetic laboratory mice. The mice, despite being fed a high-fat diet (45 percent of total calories were from fat) that simulated daily fast-food meals, gained less weight than mice that were fed a regular diet. They also maintained high energy levels.
Mice with suppressed PRCP had higher levels of alpha-MSH in their hypothalami. The effects of PRCP blockage considerably reduced their risk of developing type 2, the scientists reported.
The team was led by senior author Sabrina Diano, associate professor in Yale's departments of obstetrics, gynecology and reproductive sciences, and neurobiology. Its results were reported in the August issue of the Journal of Clinical Investigation.
The Yale findings come on the heels of a recent report from Indiana University that laboratory rodents experienced a dramatic decrease in body weight and fat mass within a week of being injected with a combination of exenatide and glucagon-two already FDA-approved drugs that are staples in diabetes treatment.
Categories: Blood Sugar, Diabetes, Diabetes, Food, Research, Type 2 Issues, Weight Loss
0 comments -
Jul 25, 2009
Diabetes Health is the essential resource for people living with diabetes- both newly diagnosed and experienced as well as the professionals who care for them. We provide balanced expert news and information on living healthfully with diabetes. Each issue includes cutting-edge editorial coverage of new products, research, treatment options, and meaningful lifestyle issues.


Email to a Friend
Send a link to this page to your friends and colleagues.